Results 21 to 30 of about 174,072,709 (188)

Soluble Suppression of Tumorigenicity-2 as a Candidate Prognostic Marker for Stroke: A Systematic Review. [PDF]

Ann Lab Med, 2023
Risk stratification of patients for incidence of stroke and its outcomes can aid in decision-making regarding treatment options and rehabilitative care. We systematically reviewed the literature to provide comprehensive evidence for the value of serum soluble suppression of tumorigenicity-2 (sST-2) in the prediction of stroke incidence and the ...
Ahmadzadeh K, Dizaji SR, Balabandian M, Ramawad HA, Yousefifard M.   +4 more
europepmc   +3 more sources

Levels of interleukin 33 and soluble suppression of tumorigenicity 2 in acute ischemic stroke [PDF]

Clinical and Experimental Neuroimmunology, 2013
AbstractAimInterleukin 33 (IL‐33) functions as an alarmin and is produced by damaged tissue. It is reported that the levels of both IL‐33 and its receptor, soluble suppression of tumorigenicity 2 (sST2), are elevated in some inflammatory diseases. As acute ischemic stroke causes local inflammation and a systemic immune response, the aim of the present ...
Yan, Jun, Lin, Clement Y. H., Pfluger, Casey M., McCombe, Pamela A.   +3 more
openaire   +4 more sources

Soluble suppression of tumorigenicity 2 associated with fulminant myocarditis in children: A retrospective observational study. [PDF]

Medicine (Baltimore), 2023
Fulminant myocarditis (FM) is associated with high mortality, and studies on soluble suppression of tumorigenicity 2 (sST2) and myocarditis are still scarce. The aim of this study was to investigate the relationship between sST2 and FM in children with myocarditis. This was a single-center retrospective clinical observational study.
Hou W, Shi T, Li Y, Li W, Xu M, Peng F.
europepmc   +3 more sources

Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure

The Anatolian Journal of Cardiology, 2017
Soluble suppression of tumorigenicity-2 (sST2), a member of the interleukin 1 receptor family, is increased in mechanical stress conditions and is produced by cardiomyocytes and cardiac fibroblasts. Elevated sST2 level is associated with the prognosis of acute coronary syndrome, pulmonary arterial hypertension, and acute and chronic heart failure (HF).
Gul, Ibrahim, Yucel, Oguzhan, Zararsiz, Abdullah, Demirpence, Ozlem, Yucel, Hasan, Zorlu, Ali, Yilmaz, Mehmet Birhan   +6 more
core   +9 more sources

Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity‐2

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundCurrent American Heart Association/American College of Cardiology guidelines recommend the GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Infarction) scores to assess myocardial infarction (MI) prognosis ...
Yariv Gerber, Susan A. Weston, Maurice Enriquez‐Sarano, Allan S. Jaffe, Sheila M. Manemann, Ruoxiang Jiang, Véronique L. Roger   +6 more
doaj   +2 more sources

Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation [PDF]

Frontiers in Cardiovascular Medicine, 2021
Objective: A more extensively fibrotic left atrium contributes to atrial fibrillation (AF) occurrence, persistence, and recurrence. The soluble suppression of tumorigenicity 2 (sST2) has emerged as a ventricular fibrotic biomarker for patients with heart
Ruopeng Tan, Ruopeng Tan, Haixu Yu, Xu Han, Yang Liu, Xiaolei Yang, Yun-Long Xia, Yun-Long Xia, Xiaomeng Yin   +8 more
doaj   +2 more sources

Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure [PDF]

JACC: Heart Failure, 2017
The aim of this study was to perform a meta-analysis of currently available data regarding the prognostic significance of soluble suppression of tumorigenecity-2 (sST2) concentration in acute heart failure (AHF).Concentration of sST2 may have prognostic value in AHF.
AIMO, ALBERTO, VERGARO, Giuseppe, RIPOLI, ANDREA, Bayes Genis, Antoni, Pascual Figal, Domingo A, de Boer, Rudolf A, Lassus, Johan, Mebazaa, Alexandre, Gayat, Etienne, Breidthardt, Tobias, Sabti, Zaid, Mueller, Christian, Brunner La Rocca, Hans Peter, Tang, W. H. Wilson, Grodin, Justin L, Zhang, Yuhui, Bettencourt, Paulo, Maisel, Alan S, PASSINO, Claudio, Januzzi, James L, EMDIN, MICHELE   +20 more
openaire   +10 more sources

Association between soluble suppression of tumorigenicity 2 and risk and severity of coronary artery disease: a case control study [PDF]

BMC Cardiovascular Disorders
Background To investigate the differential expression of soluble suppression of tumorigenicity 2 (sST2) in patients with coronary artery disease (CAD) and healthy controls, and the correlation between sST2 and the severity of coronary artery ...
Shuai Zhang, Lu Qian, Shibao Li, Zhijian Liu   +3 more
doaj   +2 more sources

Soluble Suppression of Tumorigenicity 2 is Directly Correlated with Glycated Hemoglobin in Individuals with an Average glycemia in the Normal/Prediabetes Range [PDF]

Diabetes, Metabolic Syndrome and Obesity, 2020
Amal Hasan,1 Waleed Aldhahi2,3 1Department of Immunology and Microbiology, Dasman Diabetes Institute, Kuwait City, Kuwait; 2Medical Division, Dasman Diabetes Institute, Kuwait City, Kuwait; 3Department of Medicine, Mubarak Al-Kabeer Hospital, Kuwait City,
Hasan A, Aldhahi W
doaj   +2 more sources

Prognostic Value of β1 Adrenergic Receptor Autoantibody and Soluble Suppression of Tumorigenicity-2 in Patients With Acutely Decompensated Heart Failure [PDF]

Frontiers in Cardiovascular Medicine, 2022
BackgroundBoth β1 adrenergic receptor autoantibody (β1-AA) and soluble suppression of tumorigenicity-2 (sST2) take a role in the pathological remodeling of heart failure.
Yanxiang Sun, Li Feng, Bing Hu, Jianting Dong, Liting Zhang, Xuansheng Huang, Yong Yuan   +6 more
doaj   +2 more sources